How can relapses be detected and prevented in primary systemic small-vessel vasculitides?

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 307-320

  Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Polyangiitis; Relapse; Vasculitis; Wegener's

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DISEASE COURSE; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG MONITORING; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LABORATORY TEST; MICROSCOPIC POLYANGIITIS; MORBIDITY; MORTALITY; NEPHROTOXICITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; SMALL VESSEL VASCULITIS; STAPHYLOCOCCUS INFECTION; THORAX RADIOGRAPHY; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 17644368514     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.11.003     Document Type: Review

References (66)

1. R.A. Luqmani Assessing disease activity in the systemic vasculitides Curr Opin Rheumatol 14 2002 23-28
2. D. Jayne N. Rasmussen K. Andrassy et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 2003 36-44
3. A.D. Booth M.K. Almond A. Burns et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study Am J Kid Dis 41 2003 776-784
4. X. Kyndt D. Reumaux F. Bridoux et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis Am J Med 106 1999 527-533
5. D.R. Jayne G. Gaskin C.D. Pusey & C.M. Lockwood ANCA and predicting relapse in systemic vasculitis QJM 88 1995 127-133
6. L. Guillevin P. Cohen M. Gayraud et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients Medicine (Baltimore) 78 1999 26-37
7. J. George Y. Levy C.G. Kallenberg & Y. Shoenfeld Infections and Wegener's granulomatosis - a cause and effect relationship? QJM 90 1997 367-373
8. S.A. Capizzi & U. Specks Does infection play a role in the pathogenesis of pulmonary vasculitis? Semin Resp Inf 18 2003 17-22
9. R.J. Falk S. Hogan T.S. Carey & J.C. Jennette Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis Ann Intern Med 113 1990 656-663
10. J.P. Raynauld D.A. Bloch & J.F. Fries Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis J Rheumatol 20 1993 1524-1526
11. M.F. Cotch G.S. Hoffman D.E. Yerg et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources Arthritis Rheum 39 1996 87-92
12. G.F. Duna M.F. Cotch C. Galperin et al. Wegener's granulomatosis: Role of environmental exposures Clin Exp Rheumatol 16 1998 669-674
13. P.W. Mathieson S. Thiru & D.B. Oliveira Mercuric chloride-treated brown Norway rats develop widespread tissue injury including necrotizing vasculitis Lab Investig 67 1992 121-129
14. J.M. Harper S. Thiru C.M. Lockwood & A. Cooke Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-lpr/lpr mice: a spontaneous model for human microscopic angiitis Eur J Immunol 28 1998 2217-2226
15. K.A. Russell & U. Specks Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon Rheum Dis Clin North Am 27 2001 815-832
16. A.J. Pinching A.J. Rees B.A. Pussell et al. Relapses in Wegener's granulomatosis: The role of infection BMJ 281 1980 836-838
17. M. Gordon R.A. Luqmani D. Adu et al. Relapses in patients with a systemic vasculitis QJM 86 1993 779-789
18. C.A. Stegeman J.W. Cohen Tervaert W.J. Sluiter et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis Ann Intern Med 120 1994 12-17
19. C.A. Stegeman J.W. Cohen Tervaert P.E. de Jong & C.G. Kallenberg Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis N Engl J Med 335 1996 16-20
20. E.R. Popa C.A. Stegeman C.G. Kallenberg & J.W. Cohen Tervaert Staphylococcus aureus and Wegener's granulomatosis Arthritis Res 4 2002 77-79
21. E.R. Popa & J.W. Tervaert The relation between Staphylococcus aureus and Wegener's granulomatosis: Current knowledge and future directions Intern Med 42 2003 771-780
22. F.J. van der Woude S. Lobatto H. Permin et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis Lancet 1 1985 425-429
23. B. Nölle U. Specks J. Lüdemann et al. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis Ann Intern Med 111 1989 28-40
24. J. Cohen Tervaert F. Van der Woude A.S. Fauci et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies Arch Intern Med 149 1989 2461-2465
25. R.J. Falk & J.C. Jennette ANCA are pathogenic - oh yes they are! J Am Soc Nephrol 13 2002 1977-1979
26. H. Xiao P. Heeringa P. Hu et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice J Clin Investig 110 2002 955-963
27. J. De'Oliviera G. Gaskin A. Dash et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis Am J Kid Dis 25 1995 380-389
28. T. Girard A. Mahr L.H. Noel et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study Rheumatology 40 2001 147-151
29. C.A. Langford C. Talar-Williams K.S. Barron & M.C. Sneller Use of a cyclophosphamide induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: Extended follow-up and rate of relapse Am J Med 114 2003 463-469
30. M.M. Boomsma C.A. Stegeman M.J. van der Leij et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study Arthritis Rheum 43 2000 2025-2033
31. C.A. Langford C. Talar-Williams K.S. Barron & M.C. Sneller A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance Arthritis Rheum 42 1999 2666-2673
32. W. Koldingsnes & J.C. Nossent Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis J Rheumatol 30 2003 80-88
33. J.H. Stone Wegener's granulomatosis etanercept trial research G. limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial Arthritis Rheum 48 2003 2299-2309
34. C.J. Day P. Hewins & C.O. Savage New developments in the pathogenesis of ANCA-associated vasculitis Clin Exp Rheumatol 21 2003 S35-S48
35. B.R. Ludviksson M.C. Sneller K.S. Chua et al. Active Wegener's granulomatosis is associated with HLA-DR+CD4+T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10 J Immunol 160 1998 3602-3609
36. J.J. Yang G.A. Preston D.A. Alcorta et al. Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA) Kidney Int 62 2002 1638-1649
37. V.A. Fusaro & J.H. Stone Mass spectrometry-based proteomics and analyses of serum: A primer for the clinical investigator Clin Exp Rheumatol 21 2003 S3-S14
38. W.F. Pendergraft 3rd G.A. Preston R.R. Shah et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3 Nature Med 10 2004 72-79
39. G.S. Kerr T.A. Fleisher C.W. Hallahan Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis Arthritis Rheum 36 1993 365-371
40. G.S. Hoffman G.S. Kerr R.Y. Leavitt et al. Wegener granulomatosis: An analysis of 158 patients Ann Intern Med 116 1992 488-494
41. M.C. Sneller Evaluation, treatment, and prophylaxis of infections complicating systemic vasculitis Curr Opin Rheumatol 10 1998 38-44
42. M. Gayraud L. Guillevin P. le Toumelin et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients Arthritis Rheum 44 2001 666-675
43. A. Fauci S. Wolff Wegener's granulomatosis: Studies in eighteen patients and a review of the literature Medicine 52 1973 535-561
44. G.S. Hoffman R.Y. Leavitt T.A. Fleisher et al. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide Am J Med 89 1990 403-410
45. E. Reinhold-Keller J. Kekow A. Schnabel et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis Arthritis Rheum 37 1994 919-924
46. L. Guillevin J.F. Cordier F. Lhote et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis Arthritis Rheum 40 1997 2187-2198
47. K. de Groot D. Adu C.O. Savage et al. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review Nephrol Dial Transplant 16 2001 2018-2027
48. K. Aasarod B.M. Iversen J. Hammerstrom et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement Nephrol Dial Transplant 15 2000 611-618
49. E. Reinhold-Keller C.O. Fink K. Herlyn et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate Arthritis Rheum 47 2002 326-332
50. A. Fauci B. Haynes P. Katz & S. Wolff Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years Ann Intern Med 98 1983 76-85
51. M.C. Slot J.W. Tervaert M.M. Boomsma & C.A. Stegeman Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis Arthritis Rheum 51 2004 269-273
52. M. Sneller G. Hoffman C. Talar-Williams et al. Analysis of 42 Wegener's granulomatosis patients treated with methotrexate and prednisone Arthritis Rheum 38 1995 608-613
53. C.A. Langford M.C. Sneller & G.S. Hoffman Methotrexate use in systemic vasculitis Rheum Dis Clin North Am 23 1997 841-853
54. K. de Groot M. Muhler E. Reinhold-Keller et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate J Rheumatol 25 1998 492-495
55. J.H. Stone W. Tun & D.B. Hellman Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice J Rheumatol 26 1999 1134-1139
56. P.H. Nachman S.L. Hogan J.C. Jennette & R.J. Falk Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis J Am Soc Nephrol 7 1996 33-39
57. G.S. Hoffman J.H. Stone & C.A. Langford Implications of ANCA status when switching to maintenance therapy Arthritis Rheum 2005 [in press]
58. J.H. Stone M.L. Uhlfelder D.B. Hellmann et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety Arthritis Rheum 44 2001 1149-1154
59. P. Bartolucci J. Ramanoelina P. Cohen et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients Rheumatology (Oxford) 41 2002 1126-1132
60. P. Lamprecht J. Voswinkel T. Lilienthal et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis Rheumatology (Oxford) 41 2002 1303-1307
61. U. Specks F.C. Fervenza T.J. McDonald & M.C. Hogan Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum 44 2001 2836-2840
62. E. Tatsis A. Schnabel & W.L. Gross Interferon-alpha treatment of four patients with the Churg-Strauss syndrome Ann Intern Med 129 1998 370-374
63. O. Arbach W.L. Gross & A. Gause Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade Immunobiology 206 2002 496-501
64. E. Reinhold-Keller N. Beuge U. Latza et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients Arthritis Rheum 43 2000 1021-1032
65. C.O. Savage C.G. Winearls D.J. Evans et al. Microscopic polyarteritis: presentation, pathology and prognosis QJM 56 1985 467-483
66. L. Guillevin B. Durand-Gasselin R. Cevallos et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients Arthritis Rheum 42 1999 421-430